Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06193902
Other study ID # LEU01101
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date November 13, 2023
Est. completion date June 2027

Study information

Verified date December 2023
Source Leucid Bio
Contact Clinical Operations
Phone +44 207 118 4230
Email clinops@leucid.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a dose-escalation open-label Phase 1/2a study. The purpose of this first-in-human study is to assess the safety and tolerability of LEU011 (autologous CAR T cells targeting NKG2D ligands) in patients with solid tumours.


Description:

This is a dose-finding study of the investigational immunotherapy LEU011 in patients with NKG2DL-expressing solid tumours. The study will assess the safety and tolerability of LEU011 and is designed to determine the maximum tolerated dose (MTD) of LEU011. Enrolled patients will undergo a whole blood procurement in order to manufacture LEU011. Subjects will receive LEU011 as a single IV dose following pre-conditioning chemotherapy and will be followed up for up to two years on this trial.


Recruitment information / eligibility

Status Recruiting
Enrollment 17
Est. completion date June 2027
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Histologically and/or cytologically confirmed solid tumour. 2. 18 years or older at time of consent 3. Relapsed/refractory solid tumour with no standard treatment options available or suitable (e.g. hypersensitivity reaction) and no curative approach possible. 4. Tumour expression of NKG2DL protein. The minimum requirement is the presence of one or more ligands on 10% or more cells, encompassing tumour and/ or stroma. 5. At least one target lesion measurable by RECIST v1.1 criteria on CT or MRI scanning within four weeks of treatment that has not been irradiated or has progressed since most recent radiotherapy treatment. The target lesion should not be used as a site for tumour biopsy. 6. Eastern Co-operative Oncology Performance Status of 0-1. 7. Normal cardiac function as assessed by electrocardiography and echocardiography (ECHO. Left ventricular ejection fraction must be normal according to institutional values. 8. Baseline oxygen saturation of at least 95% 9. Haematology results must show: - neutrophils >1.5 x 109/L, - platelets >100 x 109/L, - haemoglobin >90g/L, - INR <1.3. - Lymphocytes >0.4 x 109/L 10. Biochemistry results must show: - creatinine clearance > 40 mL/min/1.73 m2 (calculated using the Chronic Kidney Disease Epidemiology [CKD-EPI] equation); bilirubin <1.25 times ULN; - ALT/ AST <2.5 times ULN (<5 times ULN if liver metastases present); - Albumin > 30g/L 11. Agree to use highly effective contraception (if applicable). Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test. See section 3.3 for more details. 12. Disease amenable to biopsy. 13. Life expectancy of at least 6 months, in the investigator's opinion. 14. Written informed consent prior to any trial procedure and registration. 15. Subjects must agree to participate in an additional LTFU trial for up to 15 years after completion of this trial. Exclusion Criteria: 1. Subjects with HIV-1, HIV-2, HTLV-1, HTLV-2, active Hepatitis B, active Hepatitis C, or active Syphilis infection. Subjects without active Hepatitis B infection who are anti-core antibody positive can be considered for recruitment subject to suitability to receive nucleoside or nucleotide analogue prophylaxis. 2. Subject must not have received any anti-cancer treatment within 28 days of lymphodepletion (prior to LEU011). This criterion applies to the following additional therapies: (i) systemic corticosteroids (> 20mg prednisolone/ day); (ii) any other systemic immunomodulatory agent (but see 11 below); (iii) radiotherapy; (iv) chemotherapy; (v) endocrine therapy or (vi) any investigational medicinal product. 3. Regarding (iv) Chemotherapy: Interval is extended to 6 weeks in the case of nitrosoureas. This criterion does not apply to the use of lymphodepleting chemotherapy prior to treatment with LEU011. 4. Prior LEU011 therapy. However, prior immune checkpoint blockade (e.g. anti-PD1, PD-L1 or CTLA-4) or immune agonist antibody therapy (e.g. anti-4-1BB, OX40, CD40 etc) does not preclude participation, but there must be a washout period of 30 days prior to treatment with LEU011. 5. Concurrent use of warfarin anticoagulant therapy and other coumarins is not permissible. Other classes of anticoagulant can be given. 6. The presence of major co-morbidity such as active major medical illness of the cardiovascular, respiratory or immune system that is likely to impair ability to undergo trial therapy, such as recent myocardial infarction, congestive cardiac failure, active gastrointestinal bleeding, active gastrointestinal ulceration, inflammatory bowel disease, ischaemic heart disease, peripheral arterial disease, pneumonitis, intestinal obstruction, sepsis or uncontrolled hypertension. 7. Clinically active autoimmune disease e.g., coeliac disease (an abnormal TTG antibody test precludes recruitment) or interstitial lung disease. Sub-clinical or quiescent autoimmune disease does not exclude from participation (e.g. euthyroid patients on thyroxine replacement therapy or patients with type 1 diabetes on insulin therapy). 8. Active infection that requires antimicrobial treatment. 9. Subjects who, in the Investigator's judgement, are unlikely to complete or comply with all protocol required study visits or procedures. 10. Hypersensitivity to any component of LEU011 (e.g. Albumin or DMSO allergy). 11. Cyclophosphamide or fludarabine allergy or contraindication. 12. Pregnancy. 13. Breastfeeding. 14. Subjects who have received a live vaccine four weeks or fewer before enrolment are ineligible for recruitment to the study. During treatment and for three months after treatment with fludarabine, administration of live vaccines is prohibited. None of the currently available covid 19 vaccines are considered to be live for this purpose since all are replication defective.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
LEU011
Immunotherapy

Locations

Country Name City State
United Kingdom Guy's and St Thomas' NHS Foundation Trust London

Sponsors (1)

Lead Sponsor Collaborator
Leucid Bio

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the dose limiting toxicity, safety and tolerability of a single dose of LEU011 in subjects with NKG2DL expressing relapsed/refractory solid tumours Incidence and nature of dose limiting toxicities will be graded by American Society of Transplantation and Cellular Therapy (ASTCT) consensus criteria. 28 days post administration of LEU011 immunotherapy
Primary To identify a recommended Phase 2 dose (RP2D) of LEU011 RP2D will be the MTD. 28 days post administration of LEU011 immunotherapy
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05637034 - 68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer N/A
Terminated NCT04095091 - Real-time Tumor Localization and Guidance for Radiotherapy Using Ultrasound (US) and Magnetic Resonance (MR)
Recruiting NCT05378425 - A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab Phase 1
Not yet recruiting NCT04723810 - TumorGlow Intraoperative Molecular Imaging (IMI) Phase 1/Phase 2
Recruiting NCT06116032 - Immune Profiling for Cancer Immunotherapy Response
Recruiting NCT06090266 - A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT04416165 - Comparison of FDG and FAPI in Patients With Various Types of Cancer N/A
Recruiting NCT05620134 - Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer Phase 1/Phase 2
Recruiting NCT04750772 - Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer N/A
Recruiting NCT06022029 - A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. Phase 1
Terminated NCT01358331 - A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) Phase 1
Recruiting NCT06175221 - Autologous TLPO Vaccine Basket Phase 2
Recruiting NCT05661461 - Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment Phase 1
Active, not recruiting NCT04196530 - BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab Phase 1
Not yet recruiting NCT03731390 - GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma Phase 1
Active, not recruiting NCT03491631 - Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT04528836 - First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05221320 - Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies Phase 2
Not yet recruiting NCT04367948 - Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma N/A